Table 5.
| Between-group analysis of anthropometrics and biochemical data at baseline and 16 weeks of study | |||
| Reduction | |||
| Variable | Decaffeinated EGCG (n = 39) | Placebo (cellulose) (n = 38) | p-value |
| Anthropometric data | |||
| Weight, kg | −0.7±2.2 | −0.2±3.5 | 0.45 |
| Body mass index, kg/m2 | −0.2±0.6 | −0.1±0.9 | 0.61 |
| Waist circumference, cm | 0.7±4.2 | −0.3±4.7 | 0.35 |
| Hip circumference, cm | 0.5±3.2 | −0.5±2.6 | 0.14 |
| Waist hip ratio | −0.0±0.0 | 0.0±0.0 | 0.71 |
| Systolic blood pressure, mmHg | 1.9±16.9 | −1.7±11.7 | 0.28 |
| Diastolic blood pressure, mmHg | −0.7±11.1 | −4.1±12.6 | 0.23 |
| Heart rate, bpm | 0.8±9.1 | 0.7±7.3 | 0.96 |
| Biochemical data | |||
| Alanine transaminase (IU/L) | 0.7±12.0 | 0.2±9.1 | 0.84 |
| Creatinine, mg/dL | 0.0±0.1 | 0.0±0.1 | 0.76 |
| eGFR, % | −0.7±7.7 | 0.1±6.9 | 0.62 |
| Uric acid, mg/dL | 0.1±0.8 | 0.3±0.9 | 0.34 |
| Triglyceride, mg/dL | −2.1±38.5 | 16.4±56.6 | 0.097* |
| Total cholesterol, mg/dL | −1.9±26.9 | 0.7±33.6 | 0.71 |
| Low density lipoprotein, mg/dL | 2.1±21.2 | −3.3±29.0 | 0.36 |
| High density of lipoprotein, mg/dL | 2.7±7.8 | 0.1±6.3 | 0.11 |
| Fasting blood sugar, mg/dL | 9.0±30.3 | −0.6±25.2 | 0.13 |
| Glycemic hemoglobin, HbA1c, % | −0.0±5.5 | −0.2±0.6 | 0.24 |
| HSCRP | 0.1±0.2 | 0.1±0.2 | 0.53 |
*P<0.1